24/7 Market News Snapshot 20 August, 2024 – PainReform Ltd. Ordinary Shares (NASDAQ:PRFX)
DENVER, Colo., 20 August, 2024 (247marketnews.com) – (Nasdaq:PRFX) are discussed in this article.
PainReform Ltd. (Nasdaq:PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, is experiencing a remarkable surge in market interest, with shares skyrocketing by over 176% to $0.925 in pre-market trading—up from $0.310. This surge comes alongside a significant trading volume of 9.27 million shares, reflecting an increasing investor enthusiasm for the company’s innovative pain management solutions.
This excitement is further fueled by encouraging early results from the company’s Phase 3 bunionectomy trial for its product PRF-110, a cutting-edge formulation aimed at alleviating post-surgical pain. The trial, which has successfully enrolled 443 patients across eight clinical sites, is structured as a randomized, double-blind, and placebo-controlled study designed to assess both the efficacy and safety of PRF-110 in patients undergoing bunionectomy—a prevalent outpatient procedure.
Initial findings indicate a notably low incidence of adverse events, averaging only one per participant, thereby underscoring the product’s promising safety profile. Ehud Geller, Chairman and interim CEO of PainReform, expressed optimism regarding these preliminary safety results, highlighting the potential of PRF-110 to serve as a transformative non-opioid alternative in post-operative pain management.
PRF-110 combines the established safety of ropivacaine with recognized safe components, positioning it strongly within the extensive $12 billion post-operative pain market. Supported by comprehensive clinical and preclinical data that validate its safety and efficacy, PainReform is advancing PRF-110 towards final clinical development stages, reinforcing its commitment to enhancing patient recovery experiences while addressing the critical need for non-opioid pain relief solutions. As the company progresses, it remains focused on developing innovative approaches that prioritize patient safety and comfort in surgical recovery.